Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$174.72 USD

174.72
8,241,747

+0.30 (0.17%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $175.51 +0.79 (0.45%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pre-Markets Edge Up on JNJ Split News

by Zacks Equity Research

Pre-Markets Edge Up on JNJ Split News

Mark Vickery headshot

J&J Plans to Split in Two; Dow Up Triple Digits

by Mark Vickery

In order to focus on market growth in its Pharma division, Johnson & Johnson now plans to split its Consumer Health business into a separate entity.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, BAYRY Q3 Results, PFE COVID Pill's Strong Efficacy

by Kinjel Shah

AstraZeneca (AZN) and Bayer (BAYRY) announce Q3 results. Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially.

Zacks Equity Research

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for HDV

Zacks Equity Research

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for HDV

Zacks Equity Research

Is WisdomTree U.S. LargeCap Dividend ETF (DLN) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DLN

Zacks Equity Research

Bayer's (BAYRY) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Bayer's (BAYRY) earnings in the third quarter of 2021 beat estimates. Revenues surge year over year.

Zacks Equity Research

Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHV

Zacks Equity Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Daniel Laboe headshot

The Stock Market Rally Is Back In High Gear

by Daniel Laboe

All the major indexes are trading at record levels, but how long can this rally hold us in this extremely overbought state?

Zacks Equity Research

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2

by Zacks Equity Research

Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Zacks Equity Research

Novavax's (NVAX) Q3 Loss Widens, Revenues Lag Estimates

by Zacks Equity Research

Novavax (NVAX) reports wider-than-expected loss for the third quarter of 2021 while revenues miss estimates. Shares down.

Zacks Equity Research

Emergent (EBS) Q3 Earnings Miss, Contract Revenue View Down

by Zacks Equity Research

Emergent's (EBS) third-quarter 2021 earnings and sales miss estimates. The company tightens the revenue guidance on lower anticipated revenues from the CDMO segment. Stock down in after-market trading.

Zacks Equity Research

Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.

Zacks Equity Research

Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWD

Zacks Equity Research

Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.

Zacks Equity Research

Halozyme (HALO) Beats on Q3 Earnings, Tweaks 2021 Guidance

by Zacks Equity Research

Halozyme (HALO) third-quarter earnings and sales beat estimates. The company raises the lower end of its previously guided range for earnings and revenues for 2021. Stock up.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VYM

Zacks Equity Research

Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VTV

Zacks Equity Research

AbbVie's (ABBV) Q3 Earnings Beat, 2021 EPS Guidance Raised

by Zacks Equity Research

AbbVie (ABBV) beats third-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares increased following the results.

Zacks Equity Research

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Zacks Equity Research

Alkermes (ALKS) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Alkermes' (ALKS) earnings in the third quarter of 2021 beat estimates while revenues miss the same. The company reiterates financial guidance for the ongoing year.

Zacks Equity Research

Glaxo (GSK) Beats on Q3 Earnings, Gives Improved EPS View

by Zacks Equity Research

Glaxo's (GSK) revenues benefit from the recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.